Sanofi (SAN.PA)
Chart Events
Performance Outlook
| Previous Close | 100.06 |
| Open | 100.72 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 100.56 - 102.70 |
| 52 Week Range | 80.95 - 106.66 |
| Volume | |
| Avg. Volume | 2,675,843 |
| Market Cap | 128.416B |
| Beta (5Y Monthly) | 0.44 |
| PE Ratio (TTM) | 20.87 |
| EPS (TTM) | 4.90 |
| Earnings Date | Apr 26, 2022 - May 02, 2022 |
| Forward Dividend & Yield | 3.33 (3.34%) |
| Ex-Dividend Date | May 06, 2022 |
| 1y Target Est | 110.74 |
- Barrons.com
Sanofi Receives Another Approval for Blockbuster Drug Dupixent
The go-ahead covers a chronic inflammatory disease for which the Food and Drug Administration has never before approved a treatment.
- GlobeNewswire
Press Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of FDA’s Priority Review action date Dupixent 300 mg weekly significantly improved signs and symptoms of eosinophilic esophagitis compared to placebo in a Phase 3 trial, underscoring the role of type 2 inflammation in this c
- PR Newswire
FDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis
Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States; approval granted more than two months ahead of FDA's Priority Review action date
